Clinical Trials
57 trialsReduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
PONS
GWT-TUD GmbH
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center
T-cell Depleted Alternative Donor Transplantation
Wake Forest University Health Sciences
AFR22
Institut Bergonié
MSC and HSC Coinfusion in Mismatched Minitransplants
University of Liege
MACS0254
Novartis
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Novartis
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
Post Transplant Donor Lymphocyte Infusion
Masonic Cancer Center, University of Minnesota
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Emory University
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
M.D. Anderson Cancer Center
Nilotinib Plus Pegylated Interferon-α2b in CML
Amsterdam UMC, location VUmc
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
M.D. Anderson Cancer Center
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Indiana University
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
Masonic Cancer Center, University of Minnesota
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Celldex Therapeutics
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
University of Arizona
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Haplo/Cord
Medical College of Wisconsin
Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia
M.D. Anderson Cancer Center
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
M.D. Anderson Cancer Center
Haploid Allogeneic Transplant Using the CliniMACS System
Stanford University
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Teva Branded Pharmaceutical Products R&D, Inc.
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
M.D. Anderson Cancer Center
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
University of Virginia
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
Bristol-Myers Squibb
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
The Emmes Company, LLC
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
MPDMDSBMT
Baylor College of Medicine
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
H. Lee Moffitt Cancer Center and Research Institute
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevecâ„¢
Agenus Inc.